


Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **"Version with markings to show changes made."**

Applicants believe that no fee is due with the submission of this Preliminary Amendment. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 15966-654 CIP (Cura-154 CIP).

### CONCLUSION

On the basis of the foregoing amendment and remark, Applicants respectfully submit that the pending claims are in condition for allowance. Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Christina V. Karnakis, Reg. No. 45,899

Attorney(s) for Applicants

c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: January 18, 2002

**Version with markings to show changes made****In the Specification:**

Table 25 on page 105 has been amended as follows:

**Table 25.**

Gene: AL135841\_B

Probe Name: Ag431

Primers	Sequences	Length	Start Position
Forward	5'-AGTCACTTCACCTGCAAGATCCT-3' (SEQ ID NO:[25] <u>24</u> )	23	581
Probe	TET-5'-CCGCATGCCAGCTTCAGCACTG-3'-TAMRA (SEQ ID NO:[26] <u>25</u> )	22	
Reverse	5'-CTTCGCTGACCGACGTGTT-3' (SEQ ID NO:[27] <u>26</u> )	19	629

TRA 1620050v1